Related Experiment Video

Updated: Mar 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

BRAF-Directed Therapy in Metastatic Colorectal Cancer

Krittiya Korphaisarn1, Scott Kopetz

  • 1From the *Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand; and †Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

Cancer Journal (Sudbury, Mass.)
|June 25, 2016
PubMed

Insights

Targeting BRAF V600E mutations in metastatic colorectal cancer is crucial. Combination therapies blocking BRAF and alternative pathways show promise, offering new treatment strategies for this challenging cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Activating BRAF mutations, primarily V600E, are found in 5-10% of metastatic colorectal cancer (mCRC) patients.
  • BRAF V600E mutations are linked to specific clinical and pathological characteristics in mCRC.
  • Current treatments targeting BRAF mutations in mCRC are limited, with monotherapy showing low efficacy.

Purpose of the Study:

  • To review emerging therapeutic strategies for targeting BRAF mutations in metastatic colorectal cancer.
  • To highlight the limitations of current BRAF-targeted therapies in mCRC.
  • To discuss the potential of combination therapies in overcoming resistance mechanisms.

Main Methods:

  • Literature review of preclinical and clinical studies on BRAF-targeted therapies in mCRC.
  • Analysis of data on combination strategies involving BRAF inhibitors and other pathway modulators.
  • Synthesis of information on the efficacy and safety of novel treatment approaches.

Main Results:

  • BRAF inhibitor monotherapy demonstrates limited clinical benefit in mCRC.
  • Combination strategies targeting BRAF and alternative signaling pathways show enhanced anti-tumor activity.
  • Ongoing clinical trials are evaluating various combination regimens for BRAF-mutated mCRC.

Conclusions:

  • Targeting BRAF V600E mutations in mCRC requires novel therapeutic approaches beyond monotherapy.
  • Combination therapies hold significant potential for improving outcomes in patients with BRAF-mutated mCRC.
  • Further research and clinical trials are essential to establish effective treatment paradigms.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K